Iqirvo PBC denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for iqirvo pbc are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Iqirvo (elafibranor) for PBC as Experimental

Iqirvo (elafibranor) received FDA approval for primary biliary cholangitis in 2024. Aetna's coverage policy review cycle sometimes lags behind new FDA approvals, particularly for newly approved agents in rare disease categories. An experimental denial can also occur when Aetna's claim system cannot match the submitted diagnosis and indication to an internally recognized covered use, or when the coverage policy has not yet been updated to reflect the FDA action. Because PBC is a rare, chronic, progressive liver disease with limited FDA-approved second-line options, the stakes of a delayed approval decision are significant.

## Why This Denial Is Appealable

FDA approval for the specific indication — PBC — is the direct rebuttal to an experimental denial. Aetna's medical policies are generally required to recognize FDA-approved uses as not experimental. The appeal needs to connect the confirmed PBC diagnosis to the FDA-approved labeling and, where Aetna's policy review is lagging, to provide the prescriber's clinical justification supported by the applicable professional guideline organization.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your Explanation of Benefits. Aetna must decide within 30 days (non-urgent) or 72 hours (expedited).
• External review (ACA §2719): After an adverse internal decision, request independent external review. An independent review organization applies objective standards including FDA approval status, which is dispositive. The window is generally up to four months from the denial notice.
• ERISA §503: Employer-sponsored plan members are entitled to full-and-fair review and may obtain all documents underlying Aetna's experimental determination.
• Expedited review: Request if your prescriber certifies that the standard timeline would seriously jeopardize your health given PBC's progressive nature.
• State insurance department complaint: If Aetna's policy has not been updated to reflect a current FDA approval, a state insurance department complaint can accelerate the policy review.

## Documentation to Gather

1. FDA-approved prescribing information — The prescriber's letter should reference the current FDA-approved prescribing label for Iqirvo, confirm the approved indication for PBC, and state that the patient's confirmed diagnosis and proposed use match that label. Direct Aetna to the label directly. 2. Diagnosis confirmation — Hepatologist or gastroenterologist records with a confirmed PBC diagnosis, including relevant laboratory markers and clinical assessment. 3. Prior-treatment history — Documentation of UDCA therapy: dates initiated, duration, and response assessment (reference the applicable guideline organization for how response is defined, without citing specific numeric thresholds). 4. On-label use attestation — Prescriber explicitly states the indication being treated, confirms it matches the FDA-approved labeling, and notes that the use is consistent with the applicable professional guideline organization (e.g., AASLD, EASL) recommendations for second-line PBC therapy. 5. Applicable guideline reference — The prescriber may reference the relevant guideline organization's recommendations for second-line PBC management to reinforce that this is standard-of-care, not experimental, practice.

## Criteria-Mapping Structure

Obtain Aetna's current experimental/investigational coverage policy and any PBC-specific drug policy. For each stated criterion:

• FDA approval status for the claimed indication — link to the prescribing label, note the approval date
• Confirmed PBC diagnosis matching the approved indication — specialist records
• Inadequate response to or intolerance of prior therapy (reference the prescribing label and applicable guideline organization for response criteria)
• Prescriber specialty and clinical rationale for Iqirvo
• Alignment with current professional guideline recommendations — reference the organization, not specific numbers

Submitting a cover letter that walks Aetna's reviewer step-by-step from the FDA label through the diagnosis records to the prescriber's clinical rationale is the most direct path to overturning this denial at the internal appeal level.